Rocket


Overview
Financials
News + Filings
Key Docs
Charts
Ownership
Insiders


All
All (ex-4s)
10-K
10-Q
8-K
3,4,5
Proxy
Prospectus
Other
Tags
Quarterly results
Appointed director
Tobira Therapeutics, Inc. (TBRA) Create: Alert

All | News | Filings
Date FiledTypeDescription
08/09/2016 8-K Form 8-K - Current report
05/09/2016 8-K Quarterly results
Docs: "Tobira Therapeutics Reports First Quarter 2016 Financial and Business Results Conference Call to be Held Today at 4:30 p.m. Eastern Time"
03/03/2016 8-K Quarterly results
Docs: "Exhibit 99.1 Tobira Therapeutics Reports Fourth Quarter 2015 Financial and Year-End Business Results Cash Balance of $62.8 million On Track to Report CENTAUR NASH Phase 2b Study Primary Endpoint in Third Quarter Conference Call to be Held Today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., March 3, 2016 /PRNewswire/ -- Tobira Therapeutics, Inc. , a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the three and 12 months ended December 31, 2015. "We had an excellent finish to the year with the presentation of patient demographic data from our CENTAUR Phase 2b study, showing that the population enrolled in this study is ..."
11/10/2015 8-K Quarterly results
Docs: "Exhibit 99.1 Tobira Therapeutics Reports Third Quarter 2015 Financial Results Conference Call to be Held Today at 4:30 p.m. Eastern Time SOUTH SAN FRANCISCO, Calif., Nov. 10, 2015 /PRNewswire/ -- Tobira Therapeutics, Inc. , a biopharmaceutical company developing novel treatments for non-alcoholic steatohepatitis and other serious immuno-inflammatory and fibrotic diseases, today reported business highlights and financial results for the third quarter of 2015. "We are making excellent progress on CENTAUR, our Phase 2b study of cenicriviroc for the treatment of NASH and liver fibrosis. CENTAUR is a well-powered large Phase 2b NASH study that has completed enrollment and exclusively enrolled patients at greater risk of progression to cirrhosis. The study was designed to include key seconda..."
08/11/2015 8-K Quarterly results
Docs: "Tobira Therapeutics Reports Second Quarter 2015 Financial Results"
11/05/2014 8-K Quarterly results
Docs: "Regado Biosciences Announces Third Quarter 2014 Financial Results and Provides Corporate Update"
08/11/2014 8-K Quarterly results
Docs: "Regado Biosciences Announces Second Quarter 2014 Financial Results and Corporate Highlights Conference Call and Webcast, August 12, 2014, at 8:30 a.m. EDT Basking Ridge, N.J. - August 11, 2014 - Regado Biosciences, Inc. , a biopharmaceutical company focused on the Phase 3 clinical development of Revolixys™ Kit , its first-in-class, actively controllable antithrombotic drug system, today announced its second quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held, August 12, 2014, at 8:30 a.m. EDT. SECOND QUARTER 2014 FINANCIAL SUMMARY Cash and cash equivalents at June 30, 2014, totaled $72.7 million compared to $30.7 million at December 31, 2013. Regado's net loss for the quarter ended June 30, 2014, was $21.4 million or a ..."
05/14/2014 8-K Quarterly results
Docs: "Regado Biosciences Announces First Quarter 2014 Financial Results and Corporate Highlights Conference Call and Webcast, May 14, 2014, at 8:30 a.m. EDT Basking Ridge, N.J. - May 14, 2014 — Regado Biosciences, Inc. , a biopharmaceutical company focused on the late-stage, Phase 3 clinical development of the Revolixys™ Kit , its first-in-class, actively controllable antithrombotic drug system, today announced its first quarter 2014 corporate highlights and financial results. A conference call and webcast to discuss the results will be held, May 14, 2014, at 8:30 a.m. EDT. “As announced in April, we were very pleased to reach the first enrollment milestone in our global REGULATE-PCI trial, which allowed us to expand our efforts and enroll ‘all comers' into the trial, and include NSTEMI pat..."

Rocket Data Systems, Inc. © 2019 | Contact Us | Data Disclaimer | Terms of Use | Privacy